ECALTA

This brand name is authorized in Austria, Brazil, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Ireland, Lithuania, Netherlands, Poland, Romania, Spain, Tunisia, UK.

Active ingredients

The drug ECALTA contains one active pharmaceutical ingredient (API):

1	Anidulafungin UNII 9HLM53094I - ANIDULAFUNGIN
	Anidulafungin is a semi-synthetic echinocandin, a lipopeptide synthesised from a fermentation product of Aspergillus nidulans. Anidulafungin selectively inhibits 1,3-β-D glucan synthase, an enzyme present in fungal, but not mammalian cells.
	Read more about Anidulafungin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ECALTA Powder for concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J02AX06	Anidulafungin	J Antiinfectives for systemic use → J02 Antimycotics for systemic use → J02A Antimycotics for systemic use → J02AX Other antimycotics for systemic use
Discover more medicines within J02AX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	522718020073317, 522718020073417
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	29995-09-11
EE	Ravimiamet	1457041
ES	Centro de información online de medicamentos de la AEMPS	07416002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	059644
FR	Base de données publique des médicaments	60614273
GB	Medicines & Healthcare Products Regulatory Agency	166379
LT	Valstybinė vaistų kontrolės tarnyba	1050550
NL	Z-Index G-Standaard, PRK	85448
PL	Rejestru Produktów Leczniczych	100180542
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64932001
TN	Direction de la Pharmacie et du Médicament	8013151H